Adjuvant Radiotherapy for Male Breast Carcinoma

İlknur Fevziye Aytaş; Rahşan Habiboğlu; Haluk Sayan; Ferit Çetinyokuş; Salih  Zeki Çakar; Sercan Ceylan Özyurt; Nalan Aslan

Adjuvant Radiotherapy for Male Breast Carcinoma

Yıl 2012, Cilt: 9 Sayı: 3, - , 01.09.2012

İlknur Fevziye Aytaş Rahşan Habiboğlu Haluk Sayan Ferit Çetinyokuş Salih Zeki Çakar Sercan Ceylan Özyurt Nalan Aslan

Öz

Breast cancer accounts for 0.2%-1.5% of all malignant tumors in males and 1% of all breast cancers. Unfortunately, to date, almost all data concerning its treatment and prognostic factors have been obtained from epidemiological and clinical studies involving only females, although the incidence of male breast cancer is increasing. Herein, we present male breast cancer patients at our center. This study included 10 consecutive male patients with a diagnosis of breast cancer. All the patients were treated between January 2002 and February 2010. The median age of the patients was 69.5 years (range: 57-85 years) at presentation, and all underwent surgical treatment. Two of the patients were not given chemotherapy, one because of bone metastasis and the other due to advanced age. Curative radiotherapy was performed in all but 1 of the patients. Median follow-up was 36 months (range: 7-77 months). Although prognostic factors in male breast cancer patients are similar to those in females, and early diagnosis and use of adjuvant treatment (radiotherapy, hormone therapy, and chemotherapy) decreases the rate of local recurrence and increases survival similarly as in females, additional research is necessary for determining the optimal treatment strategy for this disease in males. Key words: Male, breast cancer, adjuvant radiotherapy Erkek

Anahtar Kelimeler

-

Kaynakça

Shah P, Robbani I, Shah O. Clinicopathological study of male breast carcinoma: 24 years of experience. Ann Saudi Med 2009; 29:288-93.
Atahan L, Yildiz F, Selek U, et al. . Postoperative radio- therapy in the treatment of male breast carcinoma: a single institute experience. J Natl Med Assoc 2006;98: 63.
Giordano SH, Perkins GH, Broglio K, et al. Adjuvant sys- temic therapy for male breast carcinoma. Cancer 2005; :2359-64.
Rai B, Ghoshal S, Sharma SC. Breast cancer in males: a PGIMER experience. J Cancer Res Ther 2005;1:31-3.
Winchester DJ. Male breast carcinoma: a multiinstitu- tional challenge. Cancer 1998;1(83):399-400.
Vinod SK, Pendlebury SC. Carcinoma of the male breast: a review of adjuvant therapy. Australas Radiol 1999;43:69-72.
Donegan WL, Redlich PN, Lang PJ, et al. Carcinoma of the breast in males: a multiinstitutional survey. Cancer 1999; : 498-509. T1N2M0 IDC + + (<5%) + (<5%) + LRM cycle CAF cGy/frc + + + C-erb B2 Type of Surgery Date of surgery Chemotherapy LRM cycle CEF cGy/ frc LRM cycle CA+T cGy/frc Radiotherapy total dose Patient status Follow-up, months Alive
ERS; Estrogen Receptor Status, PRS; Progesterone Receptor Status IDC: Infiltrating ductal carcinoma, LRM: Left radical mastectomy, RRM: Right radical mastectomy, CEF: Cyclophosphamide, epirubicin, fluorouracil, T: Tamoxifen, D: Docataxel, CE: Cyclophosphamide, epirubicin, CA: Cyclophosphamide, adriamycin, CAF: Cyclophos- phamide, adriamycin, fluorouracil